Related Experiment Video
Updated: Aug 23, 2026

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas
Jian-Zhong Qin1, Lawrence Stennett, Patricia Bacon
1Department of Pathology, Loyola University of Chicago Medical Center, Chicago, IL, USA.
Abstract:
Once melanoma metastasizes, no effective treatment modalities prolong survival in most patients. This notorious refractoriness to therapy challenges investigators to identify agents that overcome melanoma resistance to apoptosis. Whereas many survival pathways contribute to the death-defying phenotype in melanoma, a defect in apoptotic machinery previously highlighted inactivation of Apaf-1, an apoptosome component engaged after mitochondrial damage. During studies involving Notch signaling in melanoma, we observed a gamma-secretase tripeptide inhibitor (GSI; z-Leu-Leu-Nle-CHO), selected from a group of compounds originally used in Alzheimer's disease, induced apoptosis in nine of nine melanoma lines. GSI only induced G2-M growth arrest (but not killing) in five of five normal melanocyte cultures tested. Effective killing of melanoma cells by GSI involved new protein synthesis and a mitochondrial-based pathway mediated by up-regulation of BH3-only members (Bim and NOXA). p53 activation was not necessary for up-regulation of NOXA in melanoma cells. Blocking GSI-induced NOXA using an antisense (but not control) oligonucleotide significantly reduced the apoptotic response. GSI also killed melanoma cell lines with low Apaf-1 levels. We conclude that GSI is highly effective in killing melanoma cells while sparing normal melanocytes. Direct enhancement of BH3-only proteins executes an apoptotic program overcoming resistance of this lethal tumor. Identification of a p53-independent apoptotic pathway in melanoma cells, including cells with low Apaf-1, bypasses an impediment to current cytotoxic therapy and provides new targets for future therapeutic trials involving chemoresistant tumors.
Insights
A gamma-secretase inhibitor (GSI) effectively kills melanoma cells by inducing apoptosis through a p53-independent pathway. This novel approach overcomes treatment resistance and spares normal melanocytes, offering new therapeutic targets for advanced melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Metastatic melanoma is notoriously resistant to apoptosis and current therapies.
- Defects in apoptotic machinery, such as Apaf-1 inactivation, contribute to melanoma's survival.
- Identifying novel agents to overcome apoptosis resistance is crucial for improving patient outcomes.
Purpose of the Study:
- To investigate the efficacy of a gamma-secretase inhibitor (GSI) in inducing apoptosis in melanoma cells.
- To elucidate the molecular mechanisms by which GSI overcomes melanoma's resistance to cell death.
- To evaluate the therapeutic potential of GSI as a targeted treatment for melanoma.
Main Methods:
- Treatment of melanoma cell lines and normal melanocytes with GSI (z-Leu-Leu-Nle-CHO).
- Assessment of apoptosis induction, cell cycle arrest, and protein synthesis.
- Analysis of mitochondrial pathways, BH3-only protein (Bim, NOXA) expression, and p53 activation.
- Validation using antisense oligonucleotides and evaluation in cell lines with varying Apaf-1 levels.
Main Results:
- GSI induced apoptosis in all tested melanoma lines but only G2-M arrest in normal melanocytes.
- GSI-mediated killing involved new protein synthesis and a mitochondrial pathway via up-regulation of Bim and NOXA.
- Apoptosis induction was p53-independent and effective even in melanoma cells with low Apaf-1 levels.
- Antisense inhibition of NOXA significantly reduced GSI-induced apoptosis.
Conclusions:
- GSI is a potent agent for selectively killing melanoma cells while sparing normal melanocytes.
- GSI enhances BH3-only proteins to execute apoptosis, overcoming melanoma's inherent resistance.
- A p53-independent apoptotic pathway, effective in cells with low Apaf-1, offers new therapeutic targets for chemoresistant tumors.
Related Concept Videos
The Intrinsic Apoptotic Pathway
Abnormal Proliferation
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle
The Extrinsic Apoptotic Pathway

